SCHOTT Pharma And KORU Medical Systems Announce Collaboration To Advance Large Volume Subcutaneous Infusion

• The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the "Freedom System") and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC® prefillable polymer syringes (PFS), intend to collaborate on optimization of drug delivery in the large volume subcutaneous infusion market.
• When combined with pharma therapies, the joint offering will optimize the ability to administer large volumes of medication subcutaneously and streamline the pharmaceutical drug development process.
• Application of these technologies provide the potential to simplify and de-risk delivery of large volume subcutaneous therapies in both administration by healthcare professionals in a clinic setting or patient self-administration in the home setting.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ:KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. "We want to ensure that medications are safe and easy to use for patients and care providers around the world. By combining KORU Medical's expertise in pump devices with our expertise in large-volume prefillable polymer syringes, we can help improve the time-to-market of infusion therapies while simplifying the subcutaneous drug infusion of large volume drugs," says Andreas Reisse, CEO of SCHOTT Pharma. The solution particularly addresses the market for treatments that are administered subcutaneously and require recurring dosing regimens, such as chronic diseases or cancer. The prefillable polymer syringes from SCHOTT Pharma that are used with KORU Medical's Freedom System are available in large-volume formats from 5mL to 50mL to meet the need for larger infusion volumes and higher drug viscosities.